What is the long-term trend for Travere Therapeutics, Inc.'s research and development expense?

Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s research and development expense has grown at a 0.6% compound annual growth rate (CAGR), from $201.16M to $206.01M.

Travere Therapeutics, Inc. TVTX Research and development expense

Research and development expense at other companies

Vertex PharmaceuticalsVRTX

——

Viridian Therapeutics, Inc.VRDN

——

BiogenBIIB

——

Segments

By segment

See full

Reportable Segment$57.09M+21.8%

Other financials

Income statement

See full

Revenue$127.2M+55.6%

Gross profit$125.2M+62.5%

Operating income-$36.9M+13.5%

Net income-$37.1M+10.0%

EPS (diluted)-$0.40+14.9%

Balance sheet

See full

Cash & equivalents$78.4M+26.6%

Total debt$15.6M-82.6%

Total equity$98.7M+201%

Total assets$555.2M+1.2%

Cash flow

See full

Operating cash flow-$40.4M+4.3%

CapEx$140.0K—

Free cash flow-$42.5M+28.1%

Valuation

See full

Market cap$5.2B+72.3%

Profitability

See full

Gross margin98.6%+2.6pp

Operating margin-10.6%-5.0pp

Net margin-20.3%-9.5pp

FCF margin-133.9%-34.4pp

Returns & leverage

See full

Return on equity-706%-1,302pp

Debt / equity0.2×-2.6×

Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s research and development expense?: Travere Therapeutics, Inc. (TVTX) reported research and development expense of $57.09M in Q1 2026.
How has Travere Therapeutics, Inc.'s research and development expense changed year-over-year?: Travere Therapeutics, Inc.'s research and development expense increased by 21.8% year-over-year, from $46.89M to $57.09M.
What is the long-term trend for Travere Therapeutics, Inc.'s research and development expense?: Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s research and development expense has grown at a 0.6% compound annual growth rate (CAGR), from $201.16M to $206.01M.